Recommended Articles
Fundraising

T-Therapeutics Raises $133 Million Series B for Cancer and Autoimmune Therapies

By Angeled · November 5, 2026 · Fundraising
T-Therapeutics Raises $133 Million Series B for Cancer and Autoimmune Therapies
T-Therapeutics Raises $133 Million Series B for Cancer and Autoimmune Therapies

T-Therapeutics, a Cambridge-based biotechnology company, announced on November 5, 2026 that it has closed an oversubscribed $133 million Series B financing. The round was co-led by new investors Advent Life Sciences and British Business Bank, with additional new investors including Johnson & Johnson Innovation–JJDC, Samsara BioCapital, M-Ventures, and Eli Lilly and Company. All existing major shareholders also participated, among them Sofinnova Partners, F-Prime, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures, Tencent, and BGF.

The proceeds will fund two first-in-class TCR-CD3 bispecific programmes — one in cancer and one in autoimmune disease — through to clinical proof-of-concept.

What T-Therapeutics is building

T-Therapeutics develops next-generation T cell receptor, or TCR, T cell engager therapeutics. The science is easier to understand by starting with the problem it tries to solve. Most targeted cancer drugs and antibodies can only reach proteins on the outside of a cell. But many of the proteins that distinguish a cancer cell from a healthy cell sit inside the cell, where antibodies cannot reach them. These are often described as undruggable targets — not because they are unimportant, but because existing drug formats cannot get at them.

T cells, the immune system's specialist killers, solve this problem naturally. Their receptors recognise fragments of internal proteins that cells display on their surface, like a flag advertising what is happening inside. T-Therapeutics is building bispecific molecules designed to exploit that mechanism: one end recognises a disease-associated target through a TCR, and the other engages CD3, a protein on T cells, to activate the T cell against the target cell.

The company's proprietary platform is called OpTiMus. According to the company, it can reach validated but previously undruggable intracellular targets — proteins inside cells whose role in disease is established but which conventional drugs cannot touch. If that claim holds up in the clinic, the platform could open up a large set of targets that are currently out of reach, in cancer and beyond.

The two lead programmes are TTX-008, a preclinical candidate aimed at various tumour types, and TTX-018, a discovery-stage candidate targeting inflammation and autoimmune disease. Both remain preclinical, meaning neither has yet been tested in humans. The Series B is specifically designed to change that, funding entry into the clinic and the generation of the first human data.

Why Big Pharma is backing a preclinical company

The investor list is the most striking feature of this round. Four pharmaceutical-linked investors are now involved: Eli Lilly and Johnson & Johnson Innovation–JJDC joined in this round, alongside the venture arms of Germany's Merck KGaA, through M-Ventures, and Sanofi, through Sanofi Ventures, which was already a shareholder. When the world's largest drugmakers invest in a company whose therapies have not yet entered the clinic, it signals that they consider the underlying platform, not just a single drug candidate, to be worth owning a piece of.

There are sound commercial reasons for that interest. TCR-based therapies have been one of the most actively researched areas in immunotherapy, but they are technically difficult. Designing a TCR that binds its target tightly enough to work, without cross-reacting with healthy tissue, is a hard engineering problem, and safety is a central concern. A platform that can generate such molecules reliably would be valuable across many diseases, which is why pharma investors are willing to back it before human data exists.

The round also marks a step up from the company's earlier financing. T-Therapeutics raised a $59 million Series A in 2023, extended in 2025 with a further $32 million, bringing the total Series A to $91 million. A $133 million Series B, oversubscribed, indicates that investor demand exceeded the amount the company set out to raise — a useful signal in a funding environment where biotech raises are scrutinised closely.

What clinical proof-of-concept means

The phrase "clinical proof-of-concept" defines what this money is buying. For a drug developer, proof-of-concept is the first evidence in humans that a therapy does what it is designed to do: engage its target, produce the intended biological effect, and show early signs of benefit at a tolerable dose.

Reaching that point is a major value inflection. Before human data, a biotech is valued largely on its science, its platform, and the credibility of its team.

Why it matters for founders and investors

For biotech founders, this round illustrates what it takes to raise a large Series B in 2026. T-Therapeutics combined three elements: a platform with a clear scientific rationale for reaching targets others cannot, a syndicate that includes strategic pharma investors as well as financial venture capital, and a concrete, near-term milestone — first-in-human data — that the money directly funds. A story built on a single asset with a distant payoff would have been a harder sell.

T-Therapeutics now faces the hardest part of drug development: proving in people what has so far been shown only in the laboratory. The $133 million gives it the runway to run that test properly, on two programmes at once.

Angeled.com connects founders with investors.

Sources: GlobeNewswire company announcement, November 5, 2026; Fierce Biotech, November 5, 2026; Dealroom, November 5, 2026; Finsmes, November 5, 2026.

Read Next